The retention of patients in antiretroviral therapy (ART) programmes is an important issue in resource-limited settings. Loss to follow up can be substantial, but it is unclear what the outcomes are in patients who are lost to programmes.
Methods and Findings
We searched the PubMed, EMBASE, Latin American and Caribbean Health Sciences Literature (LILACS), Indian Medlars Centre (IndMed) and African Index Medicus (AIM) databases and the abstracts of three conferences for studies that traced patients lost to follow up to ascertain their vital status. Main outcomes were the proportion of patients traced, the proportion found to be alive and the proportion that had died. Where available, we also examined the reasons why some patients could not be traced, why patients found to be alive did not return to the clinic, and the causes of death. We combined mortality data from several studies using random-effects meta-analysis. Seventeen studies were eligible. All were from sub-Saharan Africa, except one study from India, and none were conducted in children. A total of 6420 patients (range 44 to 1343 patients) were included. Patients were traced using telephone calls, home visits and through social networks. Overall the vital status of 4021 patients could be ascertained (63%, range across studies: 45% to 86%); 1602 patients had died. The combined mortality was 40% (95% confidence interval 33%–48%), with substantial heterogeneity between studies (P<0.0001). Mortality in African programmes ranged from 12% to 87% of patients lost to follow-up. Mortality was inversely associated with the rate of loss to follow up in the programme: it declined from around 60% to 20% as the percentage of patients lost to the programme increased from 5% to 50%. Among patients not found, telephone numbers and addresses were frequently incorrect or missing. Common reasons for not returning to the clinic were transfer to another programme, financial problems and improving or deteriorating health. Causes of death were available for 47 deaths: 29 (62%) died of an AIDS defining illness.
Citation: Brinkhof MWG, Pujades-Rodriguez M, Egger M (2009) Mortality of Patients Lost to Follow-Up in Antiretroviral Treatment Programmes in Resource-Limited Settings: Systematic Review and Meta-Analysis. PLoS ONE 4(6): e5790. doi:10.1371/journal.pone.0005790
Editor: Sean Emery, University of New South Wales, Australia
Received: February 6, 2009; Accepted: May 1, 2009; Published: June 4, 2009
Copyright: © 2009 Brinkhof et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This project was supported by UNAIDS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
In industrialized countries the prognosis of HIV infection has improved considerably since highly active antiretroviral therapy (ART) was introduced from 1995 onwards –. In low-income countries with a high burden of HIV and AIDS, ART has become more widely available in recent years. The World Health Organisation (WHO) estimates that about 3 million people were receiving ART in low- and middle-income countries by the end of 2007, a 7.5-fold increase during the past four years .
ART of individual patients and the monitoring and evaluation of treatment programmes critically depend on regular patient follow-up. Individual treatment decisions can then be made and treatment response, complication and mortality rates can be accurately estimated at the programme level , . Using data from a network of ART treatment programmes in resource-limited settings, we found that on average 21% of patients had been lost to programmes in the first six months after starting ART . Similarly, a systematic review of ART programmes in sub-Saharan Africa found that about 40% of patients were lost at two years, with large variation in retention rates between programmes .
The outcome of patients lost to follow has received relatively little attention. Patients not returning to the clinic where they initiated ART may have stopped taking antiretroviral drugs, resulting in high mortality. Alternatively, with increasing availability of ART, patients may have transferred to another programme, for example a programme closer to their place of residence. We performed a systematic review and meta-analysis of studies that determined the vital status of patients who were lost to follow-up (LTFU) after starting ART in low or middle-income countries. Our objectives were to describe mortality and causes of death among patients LTFU, to examine the reasons why patients LTFU could not be traced and why those traced alive had not returned to the clinic. Our aims were to inform the adjustment of mortality estimates for LTFU, to identify critical issues in patient registration and follow-up and inform strategies to improve patient retention and ascertainment of outcomes.
We aimed to identify studies that determined the vital status of all or a subset of patients lost to follow-up after starting ART in treatment programmes in Africa, Asia or Latin America. We searched the PubMed, EMBASE, Latin American and Caribbean Health Sciences Literature (LILACS), Indian Medlars Centre (IndMed) and African Index Medicus (AIM) databases. We limited the search to studies in humans; studies from Africa, Asia or Latin America; and studies published between January 1, 2000 and January 9, 2009. In PubMed we used a combination of free text and Medical Subject Headings (MeSH) and then adapted the search to the other databases. The searches of LILACS and AIM included Spanish, Portuguese and French terms. Further details are given in the Appendix S1.
Using similar keywords we searched the abstract databases of the Conference on Retroviruses and Opportunistic Infections (CROI, 1997–2008) ; the Conference on HIV Pathogenesis and Treatment of the International AIDS Society (IAS, 2001–2008) and the International AIDS Conference (AIDS; 2001–2008) . We used Google Scholar  to identify electronic publications ahead of print of eligible studies presented at CROI, IAS or AIDS. Finally, we included a study that was accepted for presentation at CROI 2009 conference and co-authored by one of us (M.P-R.).
We included all articles reporting studies where patients LTFU in ART programmes in Africa, Asia or Latin America were actively traced to establish their vital status. We excluded studies from high-income countries, case reports, and studies of patients who were LTFU while not on ART. Two reviewers (M.B. and M.P-R.) independently assessed the eligibility of articles and abstracts. Discrepancies were resolved in consultation with a third reviewer (M.E.).
Data were extracted in duplicate by the same two reviewers using a standardised questionnaire that covered the characteristics of the ART programme, including location and country; the number of patients enrolled and on ART; the setting (urban, semi-urban or rural); and whether the programme was public or private. We also extracted the definition of LTFU used in the different studies; the total number of patients LTFU and the number of patients traced; the methods used to trace patients (letter, telephone call, and/or home visits); and whether the study involved both patients on ART and not on ART. Discrepancies were resolved by consensus.
The main outcomes were the number of patients who could not be traced, the number who were found to be alive and the number who had died. For patients LTFU who could not be traced, we examined data on possible reasons. For patients found to be alive we extracted the reasons reported for not returning to the clinic. We classified reasons as transfer to another clinic; stopping treatment because of improved health; hospitalised or being too sick to come to the clinic; stigma and social problems; adverse effects of drugs; logistic problems and economic reasons (including cost for transport) and other reasons. Finally, for patients who were known to have died, we extracted information on the likely cause of death. Causes of death were classified as AIDS defining illness; condition not related to AIDS; unnatural cause; and unknown.
We expressed results as percentages and calculated exact binomial 95% confidence intervals for these percentages. We combined data from several studies using random-effects meta-analysis on the logit scale, and transformed combined estimates back to percentages. We then investigated, for the programmes from sub-Saharan Africa, associations between study characteristics and mortality in patients LTFU using random effects meta-regression. Study characteristics considered were: setting (2 categories: urban vs. rural/urban-rural); definition of LTFU (3 categories: missed 1 or 2 scheduled visits, missed last scheduled visit by 2–6 weeks; missed last scheduled visit by >3 months); method of tracing (3 categories: telephone call, home visit, telephone call and home visit); percentage of patients LTFU included in the survey; and percentage of patients traced and actually retrieved during the survey. Data were analysed using STATA version 10.1 (StataCorp, Texas, USA).
Figure 1 describes the process of identifying eligible studies. Among the 323 published items and 659 conference abstracts retrieved, we identified 16 eligible reports (six published articles, one published research letter, one article published electronically ahead of print and eight abstracts), which included data on 17 separate studies.
Table 1 summarises the characteristics of the 17 studies. One article  reported two studies, one from a public ART programme (No. 12 in Table 1) and one from a workplace programme (No. 13) in South Africa. Sixteen were performed in nine sub-Saharan African countries: South Africa (5 studies), Malawi (3 studies), Uganda (2 studies), Zambia, Botswana, Ethiopia, Kenya, Tanzania, and Mali (one study each). One study was from India. Figure 2 shows the geographical location of studies. Two studies (Nos. 4 and 8) ,  included both patients on ART and not on ART. We did not identify any studies in children. Most settings were urban or semi-urban; five studies were from a rural setting. Definitions of LTFU varied. Missing appointments for more than 1 month or more than 3 months was used in several studies (Table 1). Patients were traced using telephone calls, home visits or through social networks. The median duration of follow up from start of ART to last contact in patients LTFU was 1.5 months , 2.7 months , 4.3 months , 13.9 months , and not reported in the remaining 12 studies. Median times from start of ART to death in patients LTFU ranged from 1.5 to 2.9 months in the four studies , , ,  that reported this information. In addition, it is clear that in a further two studies ,  deaths among patients LTFU occurred predominantly in the first 6 months after start of ART.
Vital status of patients
The number of patients traced and their vital status are summarized in Table 2. Nine studies traced all patients LTFU during the study period and six included a subset of patients representing 15% to 53% of all patients LTFU. Two studies ,  only included patients who had agreed to being traced if LTFU when starting ART. The remaining four studies , , ,  did not report any criteria for inclusion of patients in the tracing effort. In two other studies ,  the proportion of patients LTFU included in the study was unclear. A total of 6420 patients were traced. Overall, vital status of 4021 patients (63%) could be ascertained; the percentage ascertained ranged from 45% to 87%. A total of 1602 patients had died (40%, range across studies 12% to 87%). The combined mortality from random effects meta-analysis was 40% (95% CI 33%–48%). When removing the two studies that included patients not on ART, mortality increased to 42% (95% CI 34%–50%). When further restricting the analysis to public ART programmes in sub-Saharan Africa (12 studies), mortality was 46% (95% CI: 39%–54%). In all three meta-analyses the between-study heterogeneity was substantial, with I2 values >90% and P from tests of heterogeneity <0.0001 (Figure 3).
Study-specific mortality estimates with binomial exact confidence intervals, combined estimates and confidence intervals from random effects meta-analysis. Studies including patients not on ART (# ; squares); workplace programme, programme from outside Africa ($ ; triangles).
In the studies from sub-Saharan Africa, the percentage of patients LTFU in a programme was associated with mortality in the patients LTFU (p from meta-regression model = 0.02). The estimated mortality in patients LTFU declined from around 60% to 20% as the percentage of patients LTFU in the programme increased from 5% to 50% (Figure 4). The association was similar when excluding the two studies ,  that included some patients not on ART, or the study in a South African mine . There was little evidence that in addition to the percentage of patients LTFU mortality varied with other characteristics, including the setting of the programme (p = 0.51), definition of LTFU used (p = 0.90), method of tracing (p = 0.75), the proportion of patients LTFU included in the survey (p = 0.73), and the proportion of patients successfully traced (p = 0.80).
Reasons why patients were not found
Seven studies –, , , ,  provided information on the reasons why the tracing of 401 patients was unsuccessful. The majority of patients (333, 83%) were not found because of an incorrect, incomplete or missing telephone number or home address in the patient file. Sixty-four patients (16%) had moved to an unknown location, or a location too far from the clinic to allow a home visit. Reasons were unknown in the remaining patients. Two studies ,  mentioned inadequate contact information as the main reason why tracing failed, but did not give any figures. Three studies compared the characteristics of patients who were found to those who could not be traced , , . Two of the three studies reported that the patients not found had distributions of clinical stage, CD4 counts and viral load similar to patients found to be alive , . However, Hochgesang et al.  reported that patients who could not be found had low initial CD4 counts and suggested that many of these might have died.
Reasons for not returning to the clinic
Reasons for not returning to the clinic among patients found alive were assessed in 11 studies, for 1096 (75%) of the 1464 surviving patients (Table 3). Not all reasons were considered in all programmes, and the importance of different reasons varied across programmes. Common reasons included the transfer to another ART programme, financial problems (for example with costs of transport), and improved or deteriorating health. Stigma and social problems and adverse effects were less frequently mentioned. Other reasons reported in single studies were pregnancy or childbirth , advice from care provider , administrative problems (for example loss of patient cards)  or religious beliefs , .
Causes of death in patients LTFU
The cause of death was investigated for 128 deaths in three studies from Johannesburg, South Africa , , , using verbal autopsy. For 81 patients (63%) the cause of death remained unknown. For the other 47 deaths, the reported cause of death was an AIDS defining illness in 29 patients (62%), a condition not related to AIDS in 16 patients (34%) and an unnatural cause in two patients (4%).
This systematic review and meta-analysis of studies that traced patients who were LTFU in ART programmes in resource-limited settings showed that the outcome of over a third of patients remained unknown. All studies except one were conducted in sub-Saharan Africa and no study was done in children. Among African adults who were LTFU after starting ART and successfully traced, the combined mortality was 46%. Mortality ranged from 12% to 87% across studies, and was inversely associated with the rate of LTFU in the programmes. Incorrect or missing telephone numbers and addresses were often the reason why patients could not be located. Transfer to another programme, financial constraints and improving or deteriorating health were common reasons for not returning to the clinic.
We performed a comprehensive search of the literature, including of abstracts presented at three major HIV/AIDS conferences, thus minimizing possible publication bias. We identified studies of over 6,000 patients who were LTFU in ART programmes in 10 low- or middle-income countries. Sites were heterogeneous and included both rural and urban locations. The approach used to trace patients varied and included telephone calls, home visits and social networks. Our findings should therefore be applicable to other ART programmes, particularly in sub-Saharan Africa.
Definitions of LTFU and the assessment of reasons for not returning to the clinic were not standardized across studies, which precluded formal meta-analysis of these data, and information on causes of death was limited. Other limitations include the lack of information, in most studies, on the time of death. The limited information that is available from some studies , , ,  indicates that patients were lost in the first few months of ART, and died soon thereafter. Data from the ART in Lower Income Countries (ART-LINC) collaboration and other treatment programmes, for example the Médecins Sans Frontières (MSF) programmes in Malawi , and South Africa , showed that loss to follow-up and death mostly occur in the first six months after ART initiation.
A high risk of death in the first few months after starting ART is characteristic of resource-limited settings where most patients start therapy late with advanced disease , , . However, mortality in patients LTFU is substantially higher than the mortality commonly reported in the first year of ART based on routinely recorded deaths and, censoring of follow-up in patients LTFU , , . ART programmes with high rates of LTFU and poor ascertainment of deaths may therefore seriously underestimate mortality. Furthermore, mortality among patients LTFU differs depending on the rate of LTFU of the treatment programme: mortality declined with increasing rates of LTFU. In programmes with high rates of LTFU those LTFU might thus include a sizeable group of low-risk patients who self-transferred to another programme, for example because of a more convenient location of the new clinic, to avoid stigma or due to work-related reasons. The results of dedicated studies tracing patients LTFU can be used to correct naïve estimates of mortality in a given programme , , . In the absence of such studies, the data from this systematic review provide a sensible range of estimates of mortality in patients LTFU which can be used in sensitivity analyses to adjust overall mortality.
In most studies an important proportion of patients could not be located, and mortality of those whose vital status could be ascertained may not be representative of all patients LTFU. Contact information that is absent, incorrect or out-of-date could be related to the risk of death. For example, healthier individuals may be more mobile than sicker patients, and more likely to leave the catchment area of the clinic in search of work. Conversely, patients providing incorrect details may be part of a vulnerable group, with little social support and low adherence to ART. If results of tracing studies are likely to be affected by selection bias, correction of mortality is again best done in sensitivity analyses, using a range of plausible values. Clearly, the quality and completeness of patient's contact details should be improved and regularly updated during follow-up. Of note, a recent survey  of electronic medical record systems used in ART programmes in lower-income countries found that well managed databases might contribute to retaining patients in programmes.
An understanding of the reasons for not returning to care is important to the design of effective and cost-effective ART programmes. Outreach teams that routinely trace patients, combined with other measures, can substantially reduce LTFU , but such teams are costly, and the emphasis should be on the prevention of LTFU. Transfer to another programme was common among patients found to be alive. Strengthening of referral systems and regular exchange of information between clinics, together with patient education could increase the recording of transfers and ensure continuity of care. Unsurprisingly, financial constraints were another common reason for not returning to the clinic. Direct and indirect costs related to the provision of care have been identified as major obstacles to access to ART, acceptance of ART  and adherence to treatment , . Mortality in programmes that charge user fees has been shown to be higher than in those offering free treatment . Decentralisation of services, task shifting to lay care providers, longer drug refill periods for stable patients, as well as provision of transport vouchers for those in need are some of the strategies that could address this issue.
Other important reasons for LTFU were improvements in health, adverse effects and feeling too sick to come to the clinic or being hospitalised. Reports of stopping care as a result of perceived improved health reflect a poor understanding of the chronic nature of the disease and the need for continued, life-long ART. The experience or fear of toxicities has been found to be associated with poor adherence in previous studies , . These issues need to be addressed through training of care givers and preparing patients for ART. Interventions that are aimed at the individual (rather than groups) and provided over longer time periods (>12 weeks) have been shown to be effective in improving adherence to ART .
Stigma and social problems were also repeatedly mentioned. Fear of disclosure, social isolation or the exposure to a discouraging social network have being identified as barriers to treatment adherence in studies conducted in high and low-income settings , . In a study conducted in Botswana, Tanzania and Uganda, patients reported difficulties in taking their drugs when they were among employers, co-workers or friends to whom they had not disclosed their HIV status . The development of practical medication management skills in open discussions with patients could be beneficial in this context .
In conclusion, a substantial minority of patients LTFU cannot be traced and among those traced on average 46% of patients have died. Transfer to another programme, financial constraints and improving or deteriorating health were common reasons for not returning to the clinic. These findings have important implications both for patient care and the monitoring and evaluation of ART programmes in resource-limited settings.
(0.05 MB DOC)
We are grateful to Doris Kopp for expert help with literature searches. We would also like to thank S. Charalambous, P. Tattevin, G. Lurton and M. Maskew for providing additional information on their studies.
Analyzed the data: MWGB. Wrote the paper: MWGB MPR ME. Conceived and designed the systematic review: MWGB MPR ME. Performed data extraction: MWGB MPR.
- 1. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, et al. (1997) Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 315: 1194–1199.
- 2. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, et al. (1998) Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352: 1725–1730.
- 3. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853–860.
- 4. World Health Organization (2008) Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2008. Available: http://www.who.int/hiv/mediacenter/universal_access_progres_report_en.pdf.
- 5. Braitstein P, Brinkhof MWG, Dabis F, Schechter M, Boulle A, et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. The Lancet 367: 817–824.
- 6. Yiannoutsos CT, An M-W, Frangakis CE, Musick BS, Braitstein P, et al. (2008) Sampling-based approaches to improve estimation of mortality among patient dropouts: experience from a large PEPFAR-funded program in Western Kenya. PLoS ONE 3: e3843.
- 7. Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A, et al. (2008) Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bulletin of the World Health Organization 86: 497–576.
- 8. Rosen S, Fox MP, Gill CJ (2007) Patient retention in antiretroviral therapy programs in sub-Saharan Africa: A systematic review. PLoS Medicine 4: e298.
- 9. Conference on Retroviruses and Opportunistic Infections. Abstract Search. Available: http://www.retroconference.org/AbstractSearch/.
- 10. International AIDS Society Abstract Search. Available: http://www.iasociety.org/AbstractSearch.aspx.
- 11. Google Scholar. Available: http://scholar.google.com/.
- 12. Dahab M, Charalambous S, Karstaedt A, Hamilton R, Makoa Z, et al. (2008) Off the radar screen: comparing reasons for treatment default in a workplace ART programme and a public sector clinic in South Africa (Abstract no. THPE0123). AIDS 2008 - XVII International AIDS Conference. Mexico City, Mexico.
- 13. Krebs DW, Chi BH, Mulenga Y, Morris M, Cantrell RA, et al. (2008) Community-based follow-up for late patients enrolled in a district-wide programme for antiretroviral therapy in Lusaka, Zambia. AIDS Care 20: 311–317.
- 14. An M-W, Frangakis CE, Musick BS, Yiannoutsos CT (2009) The need for double-sampling designs in survival studies: an application to monitor PEPFAR. Biometrics 65: 301–306.
- 15. Ive P, Conradie F, Xaba S, Sanne I (2005) Causes of loss to follow up in patients taking antiretroviral therapy in the national rollout program of South Africa (Abstract no. MoPp0304). The 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brasil.
- 16. Dalal RP, Macphail C, Mqhayi M, Wing J, Feldman C, et al. (2008) Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr 47: 101–107.
- 17. Yu JK-L, Chen SC-C, Wang K-Y, Chang C-S, Makombe SD, et al. (2007) True outcomes for patients on antiretroviral therapy who are “lost to follow-up” in Malawi. Bulletin of the World Health Organization 85: 550–554.
- 18. Geng EH, Emenyonu N, Bwana MB, Glidden DV, Martin JN (2008) Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA 300: 506–507.
- 19. Bisson GP, Gaolathe T, Gross R, Rollins C, Bellamy S, et al. (2008) Overestimates of survival after HAART: implications for global scale-up efforts. PLoS ONE 3: e1725.
- 20. Maskew M, MacPhail P, Menezes C, Rubel D (2007) Lost to follow up: contributing factors and challenges in South African patients on antiretroviral therapy. S Afr Med J 97: 853–857.
- 21. Hochgesang M, Kuyenda A, Hosseinipour M, Phiri S, Weigel R, et al. (2006) Active tracing of ART patients lost to follow-up at lighthouse shows that few ‘stopped’ treatment for their own reasons, but many have died (Abstract no. TUPE0119). AIDS 2006 - XVI International AIDS Conference. Toronto.
- 22. McGuire M, Munyenyembe T, Althomsons S, Bouithy N, Le Paih M, et al. (2009) Double sampling of ART and pre-ART patients defaulting from care to determine vital outcomes in an HIV/AIDS program in rural Malawi. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada.
- 23. Billy A, Mujaki J, Johnathan S, Rwamahe S, Barongo J, et al. (2007) What does “lost to follow-up” mean for patients enrolled in an highly active antiretroviral treatment (HAART) programme in Africa? (Abstract no. CDB514). 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sidney, Australia.
- 24. Lurton G, Akondé A, Madec Y, Teisseire P, Traore T, et al. (2008) Looking for lost to follow-up patients: experience of Ségou, Mali (Abstract no. MOPE0749). AIDS 2008 - XVII International AIDS Conference. Mexico City, Mexico.
- 25. Deribe K, Hailekiros F, Biadgilign S, Amberbir A, Beyene BK (2008) Defaulters from antiretroviral treatment in Jimma University Specialized Hospital, Southwest Ethiopia. Tropical Medicine & International Health 13: 328–333.
- 26. Joshi K, Jhanwar S, Mathur A, Agarwal H, Mathur SL (2008) Barriers in adherence of ART (anti retroviral treatment): a experience of ART Centre of Western Rajasthan, India (Abstract no. CDB0504). AIDS 2008 - XVII International AIDS Conference. Mexico City, Mexico.
- 27. Muwanga A, Easterbrook P, Schaefer P, Wandera M, Okello D, et al. (2008) Losses to follow-up in a large ART program in Uganda (Abstact No. 840). 15th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts.
- 28. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, et al. (2006) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367: 1335–1342.
- 29. Boulle A, Bock P, Osler M, Cohen K, Channing L, et al. (2008) Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ 86: 678–687.
- 30. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296: 782–793.
- 31. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, et al. (2006) Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20: 1181–1189.
- 32. Forster M, Bailey C, Brinkhof MW, Graber C, Boulle A, et al. (2008) Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings. Bull World Health Organ 86: 939–947.
- 33. Zachariah R, Harries AD, Manzi M, Gomani P, Teck R, et al. (2006) Acceptance of anti-retroviral therapy among patients infected with HIV and tuberculosis in rural Malawi is low and associated with cost of transport. PLoS ONE 1: e121.
- 34. Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, et al. (2007) Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care 19: 658–665.
- 35. Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, et al. (2003) Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr 34: 281–288.
- 36. Ammassari A, Antinori A, Cozzi-Lepri A, Trotta MP, Nasti G, et al. (2002) Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr 31: Suppl 3S140–144.
- 37. Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, et al. (2001) Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 28: 445–449.
- 38. Rueda S, Park-Wyllie LY, Bayoumi AM, Tynan AM, Antoniou TA, et al. (2006) Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev 3: CD001442.
- 39. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, et al. (2006) Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 3: e438.